There is significant anticipation and positive reception in Nigeria regarding the upcoming arrival of Lenacapavir (often referred to as a “game-changer” in HIV prevention).
The drug, which is a twice-yearly injectable for pre-exposure prophylaxis (PrEP), is set for a, rollout aimed at drastically reducing new HIV infections, especially among vulnerable populations.
The Drug (“Capaville”): The drug is actually named Lenacapavir (often marketed as Sunlenca for treatment or under brand names for PrEP). It is a long-acting, twice-yearly injection that has shown up to 100% effectiveness in preventing new HIV infections in clinical trials.
A major,, landmark deal has reduced the cost of the drug from $28,000 to approximately $40 per person annually for low- and middle-income countries, making it highly accessible.
The National Agency for the Control of AIDS (NACA) is working with global health partners to distribute the drug, with training for health workers already conducted in preparation for the rollout.
This, development is expected to significantly reduce the burden of HIV in Nigeria, which has the second-largest HIV-positive population in the world.
This new, long-acting option is particularly welcomed as a replacement for daily oral PrEP, which can be difficult for users to maintain consistently, thus increasing the risk of infection.
About the Author
Why do people forget so soon?
It will now come with the caption NOT FOR USE IN SOME NATIONS.